We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Sartorius Stedim Biotech and G-Con Global Collaboration to Support Faster, More Flexible Biopharmaceutical Facility Construction

By LabMedica International staff writers
Posted on 13 Feb 2012
Print article
Sartorius Stedim Biotech (SSB; Goettingen, Germany) and G-Con (College Station, TX, USA) have agreed to collaborate globally to offer highly advanced and flexible production platforms for the biopharmaceutical manufacturing industry. The new product line will utilize G-Con Manufacturing’s novel modular, mobile clean-room pods and Sartorius Stedim Biotech’s well-established broad single-use and reusable product range to create a totally integrated production process platform.

SSB has integrated its products into unit operations for media/buffer preparation, seed fermentation, cell cultivation and harvesting, ultra-diafiltration, membrane chromatography, and viral clearance for biopharmaceutical development and manufacturing. Combining SSB’s technology with G-Con’s modular, scalable, and flexible pod platform will provide the biopharmaceutical manufacturing industry with an unparalleled set of cost-effective, plug and play tools for next-generation manufacturing facilities.

Maik Jornitz, SSB’s senior vice president of marketing for bioprocess solutions, stated, “The combined product portfolio will fundamentally change the way biopharmaceutical manufacturing processes will be designed and configured. Our integrated solutions unit will implement G-Con’s platform of modular clean-room systems into their designs. In addition, our teams will benefit from G-Con’s engineering and design expertise. Our vision is to create standardized unit operations, implemented into the self-contained G-Con modules. These modules can be used as individual process units or joined to an entire process.”

Barry Holtz, president of G-Con Manufacturing, stated, “Our common goal is to combine our complementary expertise to develop revolutionary solutions for the next-generation of flexible, single-use manufacturing concepts. We couldn’t be more excited about having an agreement with a leader in single-use products like Sartorius Stedim Biotech.”

Effective immediately, G-Con’s modular containment units are available through SSB’s integrated solutions unit and will be rolled out globally in early 2012.

Mr. Jornitz commented, “We do not want to delay the availability of the G-Con units and therefore decided to have our integrated solutions unit utilize the containment systems and G-Con’s engineering capabilities now. The global launch through our sales organizations will follow.”

Sartorius Stedim Biotech is a provider of equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management, and lab technologies are supporting the biopharmaceutical industry worldwide to develop and produce drugs safely, timely, and cost-effectively.

Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is focused on transforming science into solutions.

Headquartered in Aubagne, France, Sartorius Stedim Biotech’s manufacturing, and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany.

G-Con enables developing technologies by significantly lowering the expense and complexity of manufacturing biologic materials to good manufacturing practice (GMP) standards. The G-Con pod solution is completely self-contained and simple to maintain, reducing the need for sophisticated and expansive purpose-built facilities and specialized maintenance. Moreover, G-Con pods can be custom built in a fraction of the time required for a traditional facility and at significantly less cost. G-Con maintains an integrated product team of engineers with bioprocess development, mechanical, electrical, and heating, ventilation, and air conditioning experience combined with a regulatory and quality management system that is qualified to deliver on every size of GMP project.

Related Links:

Sartorius Stedim Biotech
G-Con

Gold Member
Troponin T QC
Troponin T Quality Control
Automated Blood Typing System
IH-500 NEXT
New
Laboratory Electric Thermostat
DNP-9025A
New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Technology

view channel
Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

Many patients with epilepsy take anti-epileptic drugs to control frequent seizures in their daily lives. To optimize treatment and avoid side effects from overdosing, it is crucial for patients to regularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.